zopolrestat has been researched along with Alloxan Diabetes in 12 studies
zopolrestat: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aldose reductase inhibitor, Zopolrestat, reduced proteinuria and albuminuria in streptozocin-induced diabetic rats compared with both untreated diabetic and age-matched controls." | 7.69 | Zopolrestat prevention of proteinuria, albuminuria and cataractogenesis in diabetes mellitus. ( Beyer-Mears, A; Cruz, E; Diecke, FP; Mistry, K, 1996) |
| "The aldose reductase inhibitor, Zopolrestat, reduced proteinuria and albuminuria in streptozocin-induced diabetic rats compared with both untreated diabetic and age-matched controls." | 3.69 | Zopolrestat prevention of proteinuria, albuminuria and cataractogenesis in diabetes mellitus. ( Beyer-Mears, A; Cruz, E; Diecke, FP; Mistry, K, 1996) |
| "45 mug equiv/g, respectively, when dosed with [(14)C]lidorestat at 10 mg/kg po)." | 1.33 | Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. ( Dicioccio, AT; Geraci, LS; Gunn, DE; Jacot, JL; Jones, JH; Jones, ML; Mitschler, A; Petrova, T; Podjarny, AD; Sawicki, DR; Sredy, J; Van Zandt, MC, 2005) |
| " In rats, its oral bioavailability is 98% and it has a favorable plasma t(1/2) (26 +/- 3 h)." | 1.33 | A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners. ( Armento, SJ; Beebe, DA; Conn, EL; Coutcher, JB; Dina, MS; Linhares, MC; Martin, WH; Mylari, BL; O'Gorman, MT; Oates, PJ; Tess, DA; Withbroe, GJ; Zembrowski, WJ, 2005) |
| "The treatment with zopolrestat restored antigen-induced protein extravazation and mast cell degranulation in the pleural cavity of diabetic sensitized rats." | 1.33 | Aldose reductase inhibitor zopolrestat restores allergic hyporesponsiveness in alloxan-diabetic rats. ( Barreto, EO; Carvalho, VF; Cordeiro, RS; e Silva, PM; Fortes, ZB; Martins, MA; Serra, MF, 2006) |
| " It is well absorbed in rats (oral bioavailability, 98%) and has a long plasma t(1/2) (26 +/- 3 h)." | 1.32 | A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-one. ( Armento, SJ; Beebe, DA; Conn, EL; Coutcher, JB; Dina, MS; Linhares, MC; Martin, WH; Mylari, BL; O'Gorman, MT; Oates, PJ; Tess, DA; Withbroe, GJ; Zembrowski, WJ, 2003) |
| "Methylguanidine was only approximately 7% as effective as aminoguanidine as an inhibitor of AGE formation from L-lysine and G6P; both compounds were poor inhibitors of AR." | 1.29 | Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. ( Chang, K; Corbett, JA; Currie, MG; Hasan, KS; McDaniel, ML; Misko, TP; Moore, WM; Petrash, JM; Smith, SR; Tilton, RG, 1993) |
| " After oral dosing, Cmax was 127 micrograms/ml for normal rats and 144 micrograms/ml for diabetic rats." | 1.28 | Pharmacokinetics of zopolrestat, a carboxylic acid aldose reductase inhibitor, in normal and diabetic rats. ( Inskeep, PB; Reed, AE; Ronfeld, RA, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (50.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mylari, BL | 3 |
| Zembrowski, WJ | 3 |
| Beyer, TA | 1 |
| Aldinger, CE | 1 |
| Siegel, TW | 1 |
| Wrobel, J | 1 |
| Millen, J | 1 |
| Sredy, J | 2 |
| Dietrich, A | 1 |
| Gorham, BJ | 1 |
| Malamas, M | 1 |
| Kelly, JM | 1 |
| Bauman, JG | 1 |
| Harrison, MC | 1 |
| Jones, LR | 1 |
| Armento, SJ | 2 |
| Beebe, DA | 2 |
| Conn, EL | 2 |
| Coutcher, JB | 2 |
| Dina, MS | 2 |
| O'Gorman, MT | 2 |
| Linhares, MC | 2 |
| Martin, WH | 2 |
| Oates, PJ | 3 |
| Tess, DA | 2 |
| Withbroe, GJ | 2 |
| Van Zandt, MC | 1 |
| Jones, ML | 1 |
| Gunn, DE | 1 |
| Geraci, LS | 1 |
| Jones, JH | 1 |
| Sawicki, DR | 1 |
| Jacot, JL | 1 |
| Dicioccio, AT | 1 |
| Petrova, T | 1 |
| Mitschler, A | 1 |
| Podjarny, AD | 1 |
| Badawy, D | 1 |
| El-Bassossy, HM | 1 |
| Fahmy, A | 1 |
| Azhar, A | 1 |
| Carvalho, VF | 1 |
| Barreto, EO | 1 |
| Serra, MF | 1 |
| Cordeiro, RS | 1 |
| Martins, MA | 1 |
| Fortes, ZB | 1 |
| e Silva, PM | 1 |
| Chen, YJ | 1 |
| Li, J | 1 |
| Quilley, J | 1 |
| Tilton, RG | 1 |
| Chang, K | 1 |
| Hasan, KS | 1 |
| Smith, SR | 1 |
| Petrash, JM | 1 |
| Misko, TP | 1 |
| Moore, WM | 1 |
| Currie, MG | 1 |
| Corbett, JA | 1 |
| McDaniel, ML | 1 |
| Tesfamariam, B | 1 |
| Gupta, S | 1 |
| Ruderman, NB | 1 |
| Cohen, RA | 1 |
| Beyer-Mears, A | 1 |
| Mistry, K | 1 |
| Diecke, FP | 1 |
| Cruz, E | 1 |
| Inskeep, PB | 1 |
| Reed, AE | 1 |
| Ronfeld, RA | 1 |
12 other studies available for zopolrestat and Alloxan Diabetes
| Article | Year |
|---|---|
Orally active aldose reductase inhibitors: indazoleacetic, oxopyridazineacetic, and oxopyridopyridazineacetic acid derivatives.
Topics: Acetates; Aldehyde Reductase; Animals; Benzothiazoles; Binding Sites; Diabetes Mellitus, Experimenta | 1992 |
Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
Topics: Administration, Oral; Aldehyde Reductase; Animals; Cattle; Chemical Phenomena; Chemistry; Diabetes M | 1991 |
A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-one.
Topics: Administration, Oral; Aldehyde Reductase; Animals; Biological Availability; Caco-2 Cells; Combinator | 2003 |
Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
Topics: Aldehyde Reductase; Animals; Cataract; Chronic Disease; Crystallography, X-Ray; Diabetes Complicatio | 2005 |
A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners.
Topics: Administration, Oral; Aldehyde Reductase; Animals; Biological Availability; Caco-2 Cells; Diabetes M | 2005 |
Aldose reductase inhibitors zopolrestat and ferulic acid alleviate hypertension associated with diabetes: effect on vascular reactivity.
Topics: Aldehyde Reductase; Animals; Antihypertensive Agents; Aorta, Thoracic; Benzothiazoles; Blood Glucose | 2013 |
Aldose reductase inhibitor zopolrestat restores allergic hyporesponsiveness in alloxan-diabetic rats.
Topics: Aldehyde Reductase; Alloxan; Aluminum Hydroxide; Animals; Benzothiazoles; Cell Count; Cell Degranula | 2006 |
Deficient renal 20-HETE release in the diabetic rat is not the result of oxidative stress.
Topics: Aldehyde Reductase; Animals; Antioxidants; Arachidonic Acid; Benzothiazoles; Cyclic N-Oxides; Cycloo | 2008 |
Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation.
Topics: Aldehyde Reductase; Amino Acid Oxidoreductases; Animals; Arginine; Benzothiazoles; Blood Pressure; B | 1993 |
Reduced Na(+)-K+ pump activity in diabetic rabbit carotid artery: reversal by aldose reductase inhibition.
Topics: Aldehyde Reductase; Animals; Benzothiazoles; Carotid Arteries; Diabetes Mellitus, Experimental; In V | 1993 |
Zopolrestat prevention of proteinuria, albuminuria and cataractogenesis in diabetes mellitus.
Topics: Albuminuria; Aldehyde Reductase; Animals; Benzothiazoles; Cataract; Chromatography, Gas; Diabetes Me | 1996 |
Pharmacokinetics of zopolrestat, a carboxylic acid aldose reductase inhibitor, in normal and diabetic rats.
Topics: Administration, Oral; Aldehyde Reductase; Animals; Benzothiazoles; Blood Proteins; Diabetes Mellitus | 1991 |